


## CLAIM AMENDMENTS

### Listing of Claims:

Claims 1-20 (canceled)

Claim 21 (new): A crystalline free base of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile (citalopram), wherein the crystalline free base has a purity of at least 99.8% w/w and includes an impurity in amounts more than 0% w/w and no more than 0.2% w/w, the impurity having the formula



wherein Z is bromine or chlorine.

Claim 22 (new): The crystalline free base of claim 21, wherein the crystalline free base is a crystalline precipitate.

Claim 23 (new): The crystalline free base of claim 21, wherein the purity of the crystalline free base is at least 99.9% w/w.

Claim 24 (new): A tablet comprising the crystalline free base of claim 21.

Claim 25 (new): A tablet comprising the crystalline free base of claim 23.

Claim 26 (new): A method of treating depression in a patient in need thereof comprising administering the crystalline free base of claim 21.

Claim 27 (new): A method of treating depression in a patient in need thereof comprising administering the crystalline free base of claim 23.

Claim 28 (new): A method of treating depression in a patient in need thereof comprising administering the tablet of claim 24.

Claim 29 (new): A method of treating depression in a patient in need thereof comprising administering the tablet of claim 25.

Claim 30 (new): The tablet of claim 24, wherein the crystalline free base of citalopram is racemic.

Claim 31 (new): The tablet of claim 25, wherein the crystalline free base of citalopram is racemic.

Claim 32 (new): The tablet of claim 24, further comprising a pharmaceutically acceptable adjuvant.

Claim 33 (new): The tablet of claim 25, further comprising a pharmaceutically acceptable adjuvant.